Category: Atherosclerosis
| Intervention | Condition | Outcome / Effect | Source | ||
|---|---|---|---|---|---|
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Type 2 Diabetes
Type 2 Diabetes Patients |
Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events comp
HR 0.92 |
— |
PMC4509601
4.7 years |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Dyslipidemia |
Fenofibrate added to simvastatin increased HDL-C by 6.3% (from 0.98 to 1.05 mmol/l) and decreased tr
HDL-C +6.3%, triglycerides -21.2% |
↑ |
PMC4509601
1 year |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Cardiovascular Disease
Type 2 Diabetes Patients |
Addition of fenofibrate to simvastatin did not significantly reduce major cardiovascular events comp
HR 0.92 |
— |
PMC4509601
4.7 years |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Cardiovascular Disease
Type 2 Diabetes Patients |
In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/
31% lower event rate |
↑ |
PMC4509601
4.7 years |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Cardiovascular Disease |
Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopa
40.1% vs 40.5% Side effects: muscle symptoms 40.1% vs 40.5%, elevated CPK 0.3%, |
— |
PMC4509601
4.7 years |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Cardiovascular Disease |
Fenofibrate added to simvastatin caused significantly more frequent serum creatinine elevations comp
Women: 27.9% vs 18.7%; Men: 36.7% vs 18. Side effects: serum creatinine elevation 27.9% in women, 36.7% i |
↓ |
PMC4509601
4.7 years |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
Cardiovascular Disease |
Fenofibrate added to simvastatin was associated with a significantly higher rate of liver enzyme ele
0.6% vs 0.2% Side effects: liver enzyme elevation (ALT >5x ULN) 0.6% vs 0.2% |
↓ |
PMC4509601
4.7 years |
| 📊 |
Fenofibrate
vs Placebo added to simvastatin ( |
significant dyslipidemia
Type 2 Diabetes Patients |
In the prespecified subgroup of T2DM patients with significant dyslipidemia (triglycerides >=204 mg/
31% lower event rate |
↑ |
PMC4509601
4.7 years |
In the overall population, adding fenofibrate to simvastatin did not significantly reduce major cardiovascular events compared to simvastatin alone (HR 0.92). (PMC4509601) However, in a prespecified subgroup of type 2 diabetes patients with significant dyslipidemia (triglycerides ≥204 mg/dl and HDL-C ≤34 mg/dl), fenofibrate plus simvastatin reduced cardiovascular event rates by 31%. (PMC4509601) Fenofibrate added to simvastatin improved lipid profiles, increasing HDL-C by 6.3% and decreasing triglycerides by 21.2%. (PMC4509601) Combination therapy did not increase the risk of myopathy compared to simvastatin alone (40.1% vs 40.5%). (PMC4509601) However, fenofibrate was associated with higher rates of serum creatinine elevation in both women (27.9% vs 18.7%) and men (36.7% vs 18.5%), and a higher rate of significant liver enzyme elevation (0.6% vs 0.2%). (PMC4509601)